Drew Spaventa
About Drew Spaventa
Drew Spaventa CEO and Chairman
Drew Spaventa is the CEO and Chairman of Singular Genomics, a biotechnology firm that he founded in 2016. As a leader in this field, Spaventa guides Singular Genomics in advancing genomic and multiomics technologies.
Serial Entrepreneur in Biotech Industry
Drew Spaventa is a seasoned entrepreneur and venture investor with deep roots in the biotech industry. Apart from founding Singular Genomics, he also founded Truvian Sciences, a company focused on developing low-volume blood testing technology. His extensive experience includes involvement in the founding of Aspen Neurosciences, which seeks to combat Parkinson’s Disease by using patient-specific stem cells.
Founding Truvian Sciences
Drew Spaventa founded Truvian Sciences, a company dedicated to creating technology for low volume blood tests. The company aims to make high-quality blood testing more accessible and convenient. As the founder, Spaventa played a critical role in driving the company’s mission and growth in the biotech sector.
Educational Background of Drew Spaventa
Drew Spaventa earned his MBA from the Rady School of Management at the University of California, San Diego. He also holds a BA in Political Science and International Relations from the University of California, San Diego. His educational background has equipped him with a robust foundation in business management and international relations, facilitating his success as an entrepreneur and investor.
Involvement with Edico Genome
Drew Spaventa was a seed investor and held an operating role in Edico Genome before its acquisition by Illumina in 2018. Edico Genome specialized in genome data analysis, and its acquisition underlined the impact and significance of Spaventa’s involvement in the company. This role further showcases his strategic acumen and expertise in the biotech industry.